uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Population pharmacokinetics of recombinant factor IX: implications for dose tailoring
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
2013 (English)In: Haemophilia, ISSN 1351-8216, E-ISSN 1365-2516, Vol. 19, no 5, 753-757 p.Article in journal (Refereed) Published
Abstract [en]

The principles of pharmacokinetic (PK) dose tailoring in clinical practice, using limited blood sampling and Bayesian PK analysis, have been described for factor VIII (FVIII). This study applied the same procedure to recombinant FIX (rFIX), i.e. population PK modelling and the use of a simplified (one-compartment) model to describe only the terminal part of the coagulation factor vs. time curve. Data from a previous study on rFIX in 56 patients (4-56years, 18-133kg) were used to define a three-compartment population PK model. The average FIX clearance was 8.4mLh(-1)kg(-1). Elimination half-life ranged between 14 and 27h. Data obtained from 24h after the infusion were found to define the terminal phase of FIX disposition. Doses to produce a target trough FIX level (set at 0.01IUmL(-1)) at 72h predicted by the Bayesian analysis, with blood sampling at either 24, 48 and 72h or at only 24 and 48h, were within -40% to +67% of those predicted using the three-compartment model, and within -57% to +125% for targeting a level at 96h. These errors were lower than the overall interindividual variance in dose requirements. As three-compartment models are needed to characterize the PK of both plasma-derived FIX and rFIX, simplification to a one-compartment model is less straightforward than for FVIII, and the methodology should be investigated further before clinical application. Limited blood sampling and Bayesian analysis could still, however, be potentially useful for targeting rFIX trough levels during prophylaxis.

Place, publisher, year, edition, pages
2013. Vol. 19, no 5, 753-757 p.
Keyword [en]
dosing, factor IX, haemophilia B, pharmacokinetics, prophylaxis
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-207506DOI: 10.1111/hae.12188ISI: 000323453200032OAI: oai:DiVA.org:uu-207506DiVA: diva2:648822
Available from: 2013-09-17 Created: 2013-09-16 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Haemophilia
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 383 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf